• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

程序性死亡受体配体1(PD-L1)是棕色脂肪细胞的一种不依赖激活的标志物。

PD-L1 is an activation-independent marker of brown adipocytes.

作者信息

Ingram Jessica R, Dougan Michael, Rashidian Mohammad, Knoll Marko, Keliher Edmund J, Garrett Sarah, Garforth Scott, Blomberg Olga S, Espinosa Camilo, Bhan Atul, Almo Steven C, Weissleder Ralph, Lodish Harvey, Dougan Stephanie K, Ploegh Hidde L

机构信息

Whitehead Institute for Biomedical Research, Cambridge, MA, 02142, USA.

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.

出版信息

Nat Commun. 2017 Sep 21;8(1):647. doi: 10.1038/s41467-017-00799-8.

DOI:10.1038/s41467-017-00799-8
PMID:28935898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5608754/
Abstract

Programmed death ligand 1 (PD-L1) is expressed on a number of immune and cancer cells, where it can downregulate antitumor immune responses. Its expression has been linked to metabolic changes in these cells. Here we develop a radiolabeled camelid single-domain antibody (anti-PD-L1 VHH) to track PD-L1 expression by immuno-positron emission tomography (PET). PET-CT imaging shows a robust and specific PD-L1 signal in brown adipose tissue (BAT). We confirm expression of PD-L1 on brown adipocytes and demonstrate that signal intensity does not change in response to cold exposure or β-adrenergic activation. This is the first robust method of visualizing murine brown fat independent of its activation state.Current approaches to visualise brown adipose tissue (BAT) rely primarily on markers that reflect its metabolic activity. Here, the authors show that PD-L1 is expressed on brown adipocytes, does not change upon BAT activation, and that BAT volume in mice can be measured by PET-CT with a radiolabeled anti-PD-L1 antibody.

摘要

程序性死亡配体1(PD-L1)在多种免疫细胞和癌细胞上表达,它可下调抗肿瘤免疫反应。其表达与这些细胞的代谢变化有关。在此,我们开发了一种放射性标记的骆驼科单域抗体(抗PD-L1 VHH),以通过免疫正电子发射断层扫描(PET)追踪PD-L1的表达。PET-CT成像显示在棕色脂肪组织(BAT)中有强烈且特异的PD-L1信号。我们证实了棕色脂肪细胞上PD-L1的表达,并证明信号强度不会因冷暴露或β-肾上腺素能激活而改变。这是第一种不依赖于其激活状态来可视化小鼠棕色脂肪的可靠方法。目前可视化棕色脂肪组织(BAT)的方法主要依赖于反映其代谢活性的标志物。在此,作者表明PD-L1在棕色脂肪细胞上表达,在BAT激活时不会改变,并且小鼠的BAT体积可以用放射性标记的抗PD-L1抗体通过PET-CT进行测量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/de5fe7ac41c2/41467_2017_799_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/684662c3c84f/41467_2017_799_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/c2408be4f192/41467_2017_799_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/de09745e2936/41467_2017_799_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/de5fe7ac41c2/41467_2017_799_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/684662c3c84f/41467_2017_799_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/c2408be4f192/41467_2017_799_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/de09745e2936/41467_2017_799_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3092/5608754/de5fe7ac41c2/41467_2017_799_Fig4_HTML.jpg

相似文献

1
PD-L1 is an activation-independent marker of brown adipocytes.程序性死亡受体配体1(PD-L1)是棕色脂肪细胞的一种不依赖激活的标志物。
Nat Commun. 2017 Sep 21;8(1):647. doi: 10.1038/s41467-017-00799-8.
2
A systematic review of imaging studies of human brown adipose tissue.一项关于人类棕色脂肪组织影像学研究的系统综述。
Ann N Y Acad Sci. 2021 Jul;1495(1):5-23. doi: 10.1111/nyas.14579. Epub 2021 Feb 18.
3
Adaptive thermogenesis in brown adipose tissue involves activation of pannexin-1 channels.棕色脂肪组织中的适应性生热涉及连接蛋白-1 通道的激活。
Mol Metab. 2021 Feb;44:101130. doi: 10.1016/j.molmet.2020.101130. Epub 2020 Nov 25.
4
A Novel PET Probe for Brown Adipose Tissue Imaging in Rodents.用于啮齿动物棕色脂肪组织成像的新型 PET 探针。
Mol Imaging Biol. 2020 Jun;22(3):675-684. doi: 10.1007/s11307-019-01426-2.
5
Adiponectin stimulates Sca1CD34-adipocyte precursor cells associated with hyperplastic expansion and beiging of brown and white adipose tissue.脂联素刺激与棕色和白色脂肪组织的增生性扩张及米色化相关的Sca1CD34脂肪细胞前体细胞。
Metabolism. 2024 Feb;151:155716. doi: 10.1016/j.metabol.2023.155716. Epub 2023 Nov 2.
6
Lipocalin 2 regulates brown fat activation via a nonadrenergic activation mechanism.脂质运载蛋白2通过非肾上腺素能激活机制调节棕色脂肪激活。
J Biol Chem. 2014 Aug 8;289(32):22063-77. doi: 10.1074/jbc.M114.559104. Epub 2014 Jun 10.
7
Beta(3)-adrenergic signaling acutely down regulates adipose triglyceride lipase in brown adipocytes.β(3)-肾上腺素能信号急性下调棕色脂肪细胞中的脂肪甘油三酯脂肪酶。
Lipids. 2010 Jun;45(6):479-89. doi: 10.1007/s11745-010-3422-3. Epub 2010 May 28.
8
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.基于治疗性抗体的PD-1/PD-L1检查点示踪剂的高分辨率PET成像
Theranostics. 2016 Jun 18;6(10):1629-40. doi: 10.7150/thno.15253. eCollection 2016.
9
Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating PD-L1 Levels in Melanoma Mouse Model.Zr 标记的抗 PD-L1 抗体片段用于评估黑色素瘤小鼠模型中的 PD-L1 水平。
Cancer Biother Radiopharm. 2020 Oct;35(8):549-557. doi: 10.1089/cbr.2019.3056. Epub 2020 Apr 21.
10
PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.用于癌症的 PD-L1 表达的同基因和人源化小鼠模型的纵向监测的 PD-L1 microSPECT/CT 成像。
Cancer Immunol Res. 2019 Jan;7(1):150-161. doi: 10.1158/2326-6066.CIR-18-0280. Epub 2018 Nov 20.

引用本文的文献

1
A pair of congenic mice for imaging of transplants by positron emission tomography using anti-transferrin receptor nanobodies.一对用于通过使用抗转铁蛋白受体纳米抗体的正电子发射断层扫描对移植进行成像的同类系小鼠。
Elife. 2025 Aug 18;14:RP104302. doi: 10.7554/eLife.104302.
2
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy.用于癌症免疫治疗的靶向CTLA-4或PD-L1的基于纳米抗体的双特异性抗体衔接子
Nat Biomed Eng. 2025 Jul 16. doi: 10.1038/s41551-025-01447-z.
3
Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.

本文引用的文献

1
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.基于治疗性抗体的PD-1/PD-L1检查点示踪剂的高分辨率PET成像
Theranostics. 2016 Jun 18;6(10):1629-40. doi: 10.7150/thno.15253. eCollection 2016.
2
Imaging of Brown Adipose Tissue: State of the Art.棕色脂肪组织的成像:当前技术水平
Radiology. 2016 Jul;280(1):4-19. doi: 10.1148/radiol.2016150390.
3
Durable antitumor responses to CD47 blockade require adaptive immune stimulation.对CD47阻断产生持久的抗肿瘤反应需要适应性免疫刺激。
使用放射性标记纳米抗体示踪剂的核成像技术进展,以支持癌症免疫治疗。
Immunother Adv. 2024 Aug 26;4(1):ltae006. doi: 10.1093/immadv/ltae006. eCollection 2024.
4
Single domain antibody: Development and application in biotechnology and biopharma.单域抗体:在生物技术和生物制药中的开发与应用。
Immunol Rev. 2024 Nov;328(1):98-112. doi: 10.1111/imr.13381. Epub 2024 Aug 21.
5
Adipocytes impact on gastric cancer progression: Prognostic insights and molecular features.脂肪细胞对胃癌进展的影响:预后见解与分子特征
World J Gastrointest Oncol. 2024 Jul 15;16(7):3011-3031. doi: 10.4251/wjgo.v16.i7.3011.
6
[F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue.F-AraG 成像显示神经炎症与棕色和骨髓脂肪组织之间存在关联。
Commun Biol. 2024 Jul 1;7(1):793. doi: 10.1038/s42003-024-06494-x.
7
Nanobody-based CAR NK cells for possible immunotherapy of MICA tumors.基于纳米抗体的嵌合抗原受体自然杀伤细胞用于MICA肿瘤的潜在免疫治疗。
PNAS Nexus. 2024 May 6;3(5):pgae184. doi: 10.1093/pnasnexus/pgae184. eCollection 2024 May.
8
Preclinical development of novel PD-L1 tracers and first-in-human study of [Ga]Ga-NOTA-RW102 in patients with lung cancers.新型 PD-L1 示踪剂的临床前开发及 [Ga]Ga-NOTA-RW102 在肺癌患者中的首次人体研究。
J Immunother Cancer. 2024 Apr 5;12(4):e008794. doi: 10.1136/jitc-2024-008794.
9
MICA-specific nanobodies for diagnosis and immunotherapy of MICA tumors.用于 MICA 肿瘤诊断和免疫治疗的 MICA 特异性纳米抗体。
Front Immunol. 2024 Mar 14;15:1368586. doi: 10.3389/fimmu.2024.1368586. eCollection 2024.
10
Pan-Cancer Analysis of PGAM1 and Its Experimental Validation in Uveal Melanoma Progression.PGAM1的泛癌分析及其在葡萄膜黑色素瘤进展中的实验验证
J Cancer. 2024 Feb 17;15(7):2074-2094. doi: 10.7150/jca.93398. eCollection 2024.
Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2646-54. doi: 10.1073/pnas.1604268113. Epub 2016 Apr 18.
4
Coinhibitory Pathways in Immunotherapy for Cancer.癌症免疫治疗中的共抑制途径。
Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.
5
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.工程化高亲和力PD-1变体用于优化免疫治疗和免疫PET成像。
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6506-14. doi: 10.1073/pnas.1519623112. Epub 2015 Nov 10.
6
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.黑色素瘤细胞内在的PD-1受体功能促进肿瘤生长。
Cell. 2015 Sep 10;162(6):1242-56. doi: 10.1016/j.cell.2015.08.052.
7
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.肿瘤微环境中的代谢竞争是癌症进展的驱动因素。
Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27.
8
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
9
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
10
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.使用放射性标记的抗 PD-L1 抗体进行肿瘤 PD-L1 表达的无创成像。
Cancer Res. 2015 Jul 15;75(14):2928-36. doi: 10.1158/0008-5472.CAN-14-3477. Epub 2015 May 14.